Article

Halting DME progression prevents vision loss

Munich, Germany-The key to minimizing vision loss associated with diabetic macular edema (DME) is to develop a treatment to prevent the edema from reaching the center of the macula, according to analyses of a study by Eli Lilly and Co.

Munich, Germany-The key to minimizing vision loss associated with diabetic macular edema (DME) is to develop a treatment to prevent the edema from reaching the center of the macula, according to analyses of a study by Eli Lilly and Co.

The study, which was presented at the 40th Annual Meeting of the European Association for the Study of Diabetes, suggests that patients have a higher risk of vision loss when DME progresses to the center of the macula.

The study involved 939 patients with various levels of DME in two trials for Lilly's ruboxistaurin, which is being investigated as a treatment for diabetic retinopathy and other diabetic microvascular complications. It is not approved anywhere in the world.

The closer the DME got to the center of the macula, the more likely it was to involve the center eventually and impair vision, the study shows.

"These findings bring us one step closer to understanding where the window of opportunity is to minimize the impact of diabetic macular edema," said Pawel Fludzinski, PhD, team leader for Lilly's ruboxistaurin effort. "It is critical that we continue to seek improved treatments and encourage screenings and early detection to help improve outcomes for the 150 million people living with diabetes."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.